A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Nov 2017 This trial has been discontinued in Spain (End date: 2017-09-22).
- 09 Nov 2017 This trial has been discontinued in Germany.